



## PRESS RELEASE

### **AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition**

**NORTH CHICAGO, Ill.**, Jan. 8, 2020 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition.

Allergan Aesthetics will operate as a new global dedicated business with its own research and development function under the AbbVie umbrella and will include leading aesthetic products including, BOTOX Cosmetic, the JUVEDERM collection of dermal fillers and COOLSCULPTING body contouring, among others. This global business, located in Irvine, California, will be led by Carrie Strom, currently Senior Vice President, U.S. Medical Aesthetics, Allergan. Upon completion of the Allergan acquisition, Ms. Strom will be named Senior Vice President, AbbVie and President, Global Allergan Aesthetics. She will oversee the worldwide operations, along with an experienced team of current Allergan leaders, and report directly to Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie.

The Eye Care and Specialty businesses – including BOTOX Therapeutics, Central Nervous System, Women’s Health and Gastrointestinal Diseases – will be integrated into the existing AbbVie organization. Several Allergan leaders have accepted leadership positions in the future company across these franchises.

The following individuals will make up the Executive Leadership team of the combined company:

- Richard A. Gonzalez, Chairman and Chief Executive Officer
- Laura Schumacher, Vice Chairman, External Affairs and Chief Legal Officer
- Michael E. Severino, M.D., Vice Chairman and President (including Research and Development)
- Carlos Alban, Vice Chairman, Chief Commercial Officer
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
- Robert A. Michael, Executive Vice President, Chief Financial Officer
- Timothy J. Richmond, Executive Vice President, Chief Human Resources Officer
- Azita Saleki-Gerhardt, Ph.D., Executive Vice President, Operations
- Carrie Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics



“We are enthusiastic about the potential of the new AbbVie and continue to make significant progress on completing our acquisition of Allergan,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Today’s announcement marks an important step forward in our plans to create the integrated global company. We are fortunate to have a leadership team with a deep breadth of both industry and company experience and we are excited to welcome the new Allergan leaders to our Company.”

**About AbbVie**

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at [www.abbvie.com](http://www.abbvie.com). Follow [@abbvie](https://twitter.com/abbvie) on Twitter or view careers on our [Facebook](#) or [LinkedIn](#) page.

*The Directors of AbbVie Inc. accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.*

*Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.*

###

**Media:**

Adelle Infante  
(847) 938-8745

**Investors:**

Liz Shea  
(847) 935-2211